Stay Updated

Sign up to our newsletter to get the latest updates

Beckley Psytech publishes peer-reviewed paper on 5-MeO-DMT in Journal of Psychopharmacology

Literature review highlights need for further clinical exploration of 5-MeO-DMT

Beckley Psytech is excited to welcome the publication of a peer-reviewed literature review in the Journal of Psychopharmacology. The paper, entitled ‘A narrative synthesis of research with 5-MeO-DMT,’ explores the pharmacology, chemistry and metabolism of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT), as well as epidemiological studies, and reported adverse and beneficial effects. The paper, authored by Anya Ermakova, research scientist, and Fiona Dunbar, Beckley Psytech Chief medical advisor, can be accessed here.

 In collaboration with leading psychedelic researchers Dr James Rucker, Institute of Psychiatry, Psychology & Neuroscience at King's College London, and Dr Matthew Johnson, this paper aimed to review all published literature to strengthen the parties’ combined knowledge of 5-MeO-DMT and inform future clinical development.

 Building on the company’s heritage, anchored in the pioneering research conducted by the Beckley Foundation, the publication of this paper, in a high impact journal for the research and clinician community, further validates Beckley Psytech’s leading role in understanding the growing evidence base supporting the medical potential of 5-MeO-DMT.

 The paper’s primary conclusion notes that 5-MeO-DMT shares core characteristics of its safety profile with other psychedelic compounds including psilocybin, therefore supporting the use of established safety precautions for psychedelic research in any future interventional clinical trials.

 Another key finding is the reportedly high rates of ego-dissolution and mystical experience with 5-MeO-DMT, as seen in similar psychedelic compounds, which are reportedly associated with long-term positive therapeutic outcomes, further supporting the growing evidence base for exploring the medical potential of 5-MeO-DMT and Beckley Psytech’s rationale for exploring this compound.

 These core findings are highly encouraging and clearly outline the further need for clinical exploration and evidence to establish the compound’s safety and efficacy profile.

 With very few clinical studies published on the effects of 5-MeO-DMT in humans, and with randomised controlled clinical trials currently ongoing to assess the safety of this compound in the clinical setting, this review is vital as well as timely, helping inform Beckley Psytech’s own controlled clinical trials into the compound’s safety, pharmacokinetic and pharmacodynamic profiles in humans.

More Like This

Company Announcements

Beckley Psytech announces partnership with Empatica in latest step of digital strategy, designed to ...

Partnership will capture behavioural and physiological signals and predictive biomarkers in Beckley Psytech’s upcoming Phase 2 clinical trials. New digital strategy aims to improve patient outcomes and safety by integrating advanced digital tools i... Read More

Company Announcements

Beckley Psytech to present at 32nd Annual Oppenheimer Healthcare Conference

Beckley Psytech Limited, a UK private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, today announces that Cosmo Feilding Mellen, Chief Executive Officer, will attend the ... Read More

Company Announcements

Beckley Psytech announces dosing of first healthy volunteers in Phase 1 clinical trial assessing saf...

Study represents continued efforts to further understand the clinical and pharmacological potential of 5-MeO-DMT. BPL-003 is Beckley Psytech’s innovative dry powder intranasal formulation of 5-MeO-DMT using FDA approved intranasal delivery devices.... Read More